HC Wainwright Issues Pessimistic Estimate for Cibus Earnings

Cibus, Inc. (NASDAQ:CBUS) – HC Wainwright reduced their FY2030 earnings per share (EPS) estimates for Cibus in a report released on Friday, May 15th. HC Wainwright analyst A. Dayal now anticipates that the company will post earnings of $2.09 per share for the year, down from their previous forecast of $2.12. The consensus estimate for Cibus’ current full-year earnings is ($1.18) per share.

Other equities analysts also recently issued reports about the stock. Weiss Ratings reiterated a “sell (e+)” rating on shares of Cibus in a report on Wednesday, January 21st. Jefferies Financial Group boosted their target price on shares of Cibus from $1.90 to $3.00 and gave the stock a “hold” rating in a report on Wednesday, March 25th. One research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $9.00.

Cibus Stock Performance

Shares of Cibus stock opened at $1.30 on Monday. The company has a market capitalization of $99.23 million, a PE ratio of -0.66 and a beta of 1.66. The company has a 50-day simple moving average of $2.01 and a two-hundred day simple moving average of $1.97. Cibus has a one year low of $1.09 and a one year high of $4.19.

Cibus (NASDAQ:CBUS) last released its quarterly earnings data on Thursday, May 14th. The company reported ($0.33) earnings per share for the quarter, missing the consensus estimate of ($0.27) by ($0.06). The firm had revenue of $1.68 million during the quarter, compared to the consensus estimate of $1.61 million. Cibus had a negative net margin of 2,366.33% and a negative return on equity of 200.87%.

Institutional Investors Weigh In On Cibus

Large investors have recently bought and sold shares of the company. PACK Private Wealth LLC purchased a new stake in Cibus in the fourth quarter valued at approximately $27,000. Dimensional Fund Advisors LP purchased a new stake in Cibus in the first quarter valued at approximately $33,000. Rockland Trust Co. purchased a new stake in Cibus in the third quarter valued at approximately $26,000. Qube Research & Technologies Ltd purchased a new stake in Cibus in the second quarter valued at approximately $39,000. Finally, OMERS ADMINISTRATION Corp purchased a new stake in Cibus in the first quarter valued at approximately $66,000. Hedge funds and other institutional investors own 33.81% of the company’s stock.

Key Cibus News

Here are the key news stories impacting Cibus this week:

• Positive Sentiment: Sidoti raised earnings estimates across several periods, including Q2 2026, Q3 2026, Q4 2026, Q1 2027, Q2 2027, Q3 2027, Q4 2027, and FY2027, signaling improved outlook for Cibus’ earnings trajectory.
• Positive Sentiment: HC Wainwright also lifted its FY2026 estimate and Q4 2026 estimate, while maintaining a longer-term path to profitability, which may have helped sentiment around the name.
• Neutral Sentiment: Despite the analyst upgrades, forecasts still call for losses in the next several years, and the company’s most recent reported quarter missed EPS expectations even as revenue came in slightly ahead.
• Negative Sentiment: Recent earnings performance remains weak, with Cibus posting a wider-than-expected loss and continuing to trade well below its recent longer-term moving averages, limiting enthusiasm.

Cibus Company Profile

Cibus, Inc is a biotechnology company specializing in precision gene editing for agricultural applications. Leveraging its proprietary Rapid Trait Development System (RTDS), Cibus develops improved crop traits without the introduction of foreign DNA. The company’s platform enables targeted modifications to plant genomes, allowing for enhanced disease resistance, herbicide tolerance and yield optimization in key row crops.

The company’s core business centers on trait development services and licensing partnerships.